SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors.

Trial Profile

SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms SORAVE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2016 Status changed from recruiting to completed.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top